Authors
Latest:
Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal CancerFang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
Latest:
Faraz Ali, MBA, on Trends in Precision Medicine for Cardiovascular DiseaseThe chief executive officer of Tenaya Therapeutics discussed the growing interest in genomic medicines in cardiology.
Latest:
The Power of Partnership in CMT Gene Therapy ResearchSusan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the origins of the CMTRF.
Latest:
Michael Severino on In Vivo Gene Editing With RNA Gene WritersThe chief executive officer of Tessera Therapeutics discussed ongoing research into developing its platform for sickle cell disease, CAR T-cell therapy, and more.
Latest:
Ami J. Shah, MD, on Reaching Normalized Hemoglobin With Gene-Edited Cell Therapy in PKDThe clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.
Latest:
Selecting Cell Therapy Targets in CancerThe chief executive and medical officers of Cytovia Therapeutics discussed the company's therapeutic targets and cell therapy scaffold.
Latest:
Vlad Hogenhuis, MD, MBA, on Developing Controllable CAR Ts for Solid TumorsThe chief executive officer of Chimera Bioengineering discussed CBIO-007 and its planned IND submission for colorectal and triple negative breast cancer.
Latest:
Brett Kopelan, MA, on the Future Treatment of Epidermolysis Bullosa With Advanced TherapeuticsIn observance of Epidermolysis Bullosa Awareness Week, the executive director of debra of America discussed how a combination of advanced and topical approaches may represent the future of EB treatment.
Latest:
Dr. Anderson on Addressing Unmet Needs in Myeloma With Descartes-11Kenneth C. Anderson, MD, discusses potentially addressing unmet needs in patients with multiple myeloma through the use of the mRNA-based CAR T-cell therapy Descartes-11.
Latest:
Jason Fontenot, PhD, on Overcoming the Challenge of Delivery for Zinc Finger Epigenetic RepressorsThe chief scientific officer of Sangamo Therapeutics discussed the company’s AAV capsid evolution research.
Latest:
As Gene Editing Technology Advances, Numerous Potential Modalities EmergeJanice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences, discussed the importance of diverse approaches to gene editing to address a variety of indications.
Latest:
CARsgen Therapeutics’ CT041 Shows Promise in Advanced Gastric/Gastroesophageal Junction AdenocarcinomaThe chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 had a manageable safety/tolerability profile and promising efficacy.
Latest:
Addressing Unmet Needs With Gene TherapyEric Crombez, PhD, senior vice president and chief medical officer of Ultragenyx Gene Therapy, discussed indications the company is targeting.
Latest:
Aimee Donald, MBChB, PhD, on Making Progress With Gene Therapy in Lysosomal Storage DiseasesThe pediatrician from Royal Manchester Children’s Hospital discussed how further research in Gaucher disease can benefit the field of rare lysosomal diseases as a whole.
Latest:
Assessing Efficacy of Fibroblast Cell Therapy in MS: Hamid Khoja, PhDThe chief scientific officer of FibroBiologics discussed efficacy findings from a phase 1/2 trial.
Latest:
Selecting Cell Therapy Targets in CancerThe chief executive and medical officers of Cytovia Therapeutics discussed the company's therapeutic targets and cell therapy scaffold.
Latest:
Donald Kohn, MD, on the Trajectory of Gene TherapyThe renowned professor from University of California Los Angeles reflected on receiving the Outstanding Achievement Award from the ASGCT.
Latest:
Continuing the Marathon of Muscular Dystrophy ResearchJeffrey Chamberlain, PhD, McCaw Endowed Chair of Muscular Dystrophy at University of Washington, shared his outlook on the trajectory of research in the field.
Latest:
Pamela Garzone, PhD, on Exploring Unknowns in CAR-T for Solid TumorsThe chief development officer of Anixa Biosciences discussed the company’s trial of a CAR-T in ovarian cancer that is looking at the effect of regional administration and lymphodepletion on efficacy.
Latest:
Alexandra Gomez-Arteaga, MD, on Expanding Eligibility for Cell Transplant With Cell TherapyThe Assistant Professor of Medicine at Weill Cornell Medical College discussed the changing cell transplant landscape.
Latest:
Challenges With Conducting Clinical Trials in Gaucher Disease: Neil Weinreb, MDThe chair of the International Collaborative Gaucher Group Registry discussed challenges in Gaucher research.
Latest:
CGTLive’s Weekly Rewind – April 8, 2022Review top news and interview highlights from the week ending April 8, 2022.
Latest:
Developing Controllable Tumor Infiltrating Lymphocyte TherapiesJan ter Meulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, discussed the potential of the cytoDRIVE platform.
Latest:
Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor CellsThe scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.
Latest:
Rawan Faramand, MD, on Evaluating Orca-T in Patients With Acute Myeloid LeukemiaThe assistant professor at Moffit Cancer Center discussed the subgroup analysis she presented at ASCO’s 2024 Annual Meeting.
Latest:
Ignacio Mata, PhD, on the Research Needed to Bring Gene Therapy to PDThe associate professor of neurology at the Cleveland Clinic Lerner Institute discussed the challenges that will need to be overcome to apply gene therapy to a complex neurological disorder like PD.
Latest:
Looking Forward in Relapsed/Refractory Multiple Myeloma TreatmentsJames Hoffman, MD, leads a discussion about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Latest:
Jennifer Kwon, PhD, on Reducing LDL Cholesterol in NHPs With Epigenome EditingThe senior scientist at Tune Therapeutics discussed preclinical research presented at the ASGCT 2023 meeting.
Latest:
Tackling Deceased Kidney Transplant and Severe Scleroderma With Cell TherapyScott Requadt, chief executive officer, Talaris Therapeutics, discussed the phase 2 FREEDOM-3 trial and preclinical studies of the cell therapy FCR-001.
Latest:
Gene Editing's Potential for COVID-19 and Other IndicationsNew human gene editing therapies, drug discoveries, targets, and CRISPR technology holds the potential to usher in a new age in medicine.
